Complete this form to receive future updates about CABLIVI and aTTP.
By checking this box you confirm that you are a US physician. You also acknowledge that you understand that the information you provide may be used by Sanofi Genzyme, their affiliates, and the business service companies working with Sanofi Genzyme to provide you with additional communications and to develop products and services which may include market research.
aTTP=acquired thrombotic thrombocytopenic purpura.
CABLIVI is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.
The most common adverse reactions (>15% of patients) were epistaxis (29%), headache (21%) and gingival bleeding (16%).
Concomitant use of CABLIVI with any anticoagulant may increase the risk of bleeding. Assess and monitor closely for bleeding with concomitant use.
There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.
CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.